Page last updated: 2024-11-07

aldosterone and Central Serous Retinopathy

aldosterone has been researched along with Central Serous Retinopathy in 6 studies

Research Excerpts

ExcerptRelevanceReference
"Spironolactone treatment was associated with the improvement of chronic CSC."6.84The relation of the serum aldosterone level and central serous chorioretinopathy - a pilot study. ( Gong, Q; Liu, QH; Sun, XH; Yuan, ST, 2017)
"The purpose of this study were to compare the levels of serum cortisol, aldosterone, testosterone, dehydroepiandrosterone (DHEA), and renin hormone between patients with central serous chorioretinopathy (CSC) and a control group, and to investigate whether there was a difference regarding serum hormone levels in patients with acute/chronic CSC."3.88The relationship between the central serous chorioretinopathy, choroidal thickness, and serum hormone levels. ( Çiloğlu, E; Dogan, NC; Unal, F, 2018)
"Spironolactone treatment was associated with the improvement of chronic CSC."2.84The relation of the serum aldosterone level and central serous chorioretinopathy - a pilot study. ( Gong, Q; Liu, QH; Sun, XH; Yuan, ST, 2017)

Research

Studies (6)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's4 (66.67)24.3611
2020's2 (33.33)2.80

Authors

AuthorsStudies
Yu, S1
Cui, K1
Wu, P1
Wu, B1
Lu, X1
Huang, R1
Tang, X1
Lin, J1
Yang, B1
Zhao, J1
He, Q1
Liang, X1
Xu, Y1
Higashide, T3
Hirooka, K3
Kometani, M3
Sugiyama, K3
Çiloğlu, E1
Unal, F1
Dogan, NC1
Brinks, J1
van Dijk, EHC1
Habeeb, M1
Nikolaou, A1
Tsonaka, R1
Peters, HAB1
Sips, HCM1
van de Merbel, AF1
de Jong, EK1
Notenboom, RGE1
Kielbasa, SM1
van der Maarel, SM1
Quax, PHA1
Meijer, OC1
Boon, CJF1
Gong, Q1
Sun, XH1
Yuan, ST1
Liu, QH1
Zhao, M1
Célérier, I1
Bousquet, E1
Jeanny, JC1
Jonet, L1
Savoldelli, M1
Offret, O1
Curan, A1
Farman, N1
Jaisser, F1
Behar-Cohen, F1

Clinical Trials (3)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
[NCT02153125]Phase 230 participants (Anticipated)Interventional2014-04-30Recruiting
Short-Term Oral Mifepristone for Central Serous Chorioretinopathy. A Placebo-controlled Dose Ranging Study of Mifepristone in the Treatment of CSC (STOMP-CSC)[NCT02354170]Phase 216 participants (Actual)Interventional2015-01-31Completed
Eplerenone for Central Serous Chorioretinopathy: A Pilot Study[NCT01822561]Phase 217 participants (Actual)Interventional2013-05-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Change in Best Corrected Visual Acuity

Visual acuity will be measured with standard eye charts, with manifest refraction at the initiation and conclusion of treatment. Although an important measure, this was not chosen as the primary outcome measure, as some patients with central serous chorioretinopathy may have a normal visual acuity when properly refracted (refraction can change with elevation of the macula by sub-retinal fluid) (NCT01822561)
Timeframe: Baseline and 1 month after treatment

InterventionlogMAR (Mean)
Patients That Took Eplerenone-0.03

Change in Macular Thickness

Automated software to calculate the thickness of the macula is standard on commercial OCT devices. Macular thickness before and after treatment will be assessed and compared. (NCT01822561)
Timeframe: Baseline and 1 month after treatment

InterventionMicrons (Mean)
Patients That Received Eplerenone-26

Change in Serum Potassium

Eplerenone can cause elevation of serum potassium. After initial screening, serum potassium was evaluated at 1 and 4 weeks after baseline. (NCT01822561)
Timeframe: Baseline and 1 month after treatment

InterventionmEq/L (Mean)
Patients That Received Eplerenone0.11

Change in Subfoveal Choroidal Thickness, Study Eye

Choroidal thickness can be measured using optical coherence tomography, and is known to be affected in patients with central serous chorioretinopathy. Thickness of the choroid under the fovea will be manually calculated in both the study eye. (NCT01822561)
Timeframe: Baseline and 1 month after treatment

Interventionmicrons (Mean)
Patients That Received Eplerenone29.8

Complete Resolution of Subretinal Fluid

Optical coherence tomography is an imaging technique capable of extremely high resolution (~5-7 microns) imaging of the macula, and is able to detect the presence and amount of subretinal fluid present, the key anatomic abnormality in Central Serous Chorioretinopathy (NCT01822561)
Timeframe: Baseline and 1 month after treatment

Interventionparticipants (Number)
Patients That Took Eplerenone0

Trials

1 trial available for aldosterone and Central Serous Retinopathy

ArticleYear
The relation of the serum aldosterone level and central serous chorioretinopathy - a pilot study.
    European review for medical and pharmacological sciences, 2017, Volume: 21, Issue:3

    Topics: Adult; Aldosterone; Central Serous Chorioretinopathy; Choroid; Female; Fluorescein Angiography; Huma

2017

Other Studies

5 other studies available for aldosterone and Central Serous Retinopathy

ArticleYear
Melatonin prevents experimental central serous chorioretinopathy in rats.
    Journal of pineal research, 2022, Volume: 73, Issue:1

    Topics: Aldosterone; Animals; Central Serous Chorioretinopathy; Choroid; Ligands; Melatonin; Rats

2022
Aldosterone as a Possible Contributor to Eye Diseases.
    Endocrinology, 2022, 12-19, Volume: 164, Issue:2

    Topics: Aldosterone; Animals; Central Serous Chorioretinopathy; Diabetic Retinopathy; Glaucoma; Macular Edem

2022
Aldosterone as a Possible Contributor to Eye Diseases.
    Endocrinology, 2022, 12-19, Volume: 164, Issue:2

    Topics: Aldosterone; Animals; Central Serous Chorioretinopathy; Diabetic Retinopathy; Glaucoma; Macular Edem

2022
Aldosterone as a Possible Contributor to Eye Diseases.
    Endocrinology, 2022, 12-19, Volume: 164, Issue:2

    Topics: Aldosterone; Animals; Central Serous Chorioretinopathy; Diabetic Retinopathy; Glaucoma; Macular Edem

2022
Aldosterone as a Possible Contributor to Eye Diseases.
    Endocrinology, 2022, 12-19, Volume: 164, Issue:2

    Topics: Aldosterone; Animals; Central Serous Chorioretinopathy; Diabetic Retinopathy; Glaucoma; Macular Edem

2022
The relationship between the central serous chorioretinopathy, choroidal thickness, and serum hormone levels.
    Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie, 2018, Volume: 256, Issue:6

    Topics: Adult; Aldosterone; Biomarkers; Central Serous Chorioretinopathy; Choroid; Dehydroepiandrosterone; F

2018
The Effect of Corticosteroids on Human Choroidal Endothelial Cells: A Model to Study Central Serous Chorioretinopathy.
    Investigative ophthalmology & visual science, 2018, 11-01, Volume: 59, Issue:13

    Topics: Aged; Aged, 80 and over; Aldosterone; Cadherins; Cells, Cultured; Central Serous Chorioretinopathy;

2018
Mineralocorticoid receptor is involved in rat and human ocular chorioretinopathy.
    The Journal of clinical investigation, 2012, Volume: 122, Issue:7

    Topics: Adult; Aldosterone; Animals; Central Serous Chorioretinopathy; Choroid; Corticosterone; Eplerenone;

2012
Mineralocorticoid receptor is involved in rat and human ocular chorioretinopathy.
    The Journal of clinical investigation, 2012, Volume: 122, Issue:7

    Topics: Adult; Aldosterone; Animals; Central Serous Chorioretinopathy; Choroid; Corticosterone; Eplerenone;

2012
Mineralocorticoid receptor is involved in rat and human ocular chorioretinopathy.
    The Journal of clinical investigation, 2012, Volume: 122, Issue:7

    Topics: Adult; Aldosterone; Animals; Central Serous Chorioretinopathy; Choroid; Corticosterone; Eplerenone;

2012
Mineralocorticoid receptor is involved in rat and human ocular chorioretinopathy.
    The Journal of clinical investigation, 2012, Volume: 122, Issue:7

    Topics: Adult; Aldosterone; Animals; Central Serous Chorioretinopathy; Choroid; Corticosterone; Eplerenone;

2012
Mineralocorticoid receptor is involved in rat and human ocular chorioretinopathy.
    The Journal of clinical investigation, 2012, Volume: 122, Issue:7

    Topics: Adult; Aldosterone; Animals; Central Serous Chorioretinopathy; Choroid; Corticosterone; Eplerenone;

2012
Mineralocorticoid receptor is involved in rat and human ocular chorioretinopathy.
    The Journal of clinical investigation, 2012, Volume: 122, Issue:7

    Topics: Adult; Aldosterone; Animals; Central Serous Chorioretinopathy; Choroid; Corticosterone; Eplerenone;

2012
Mineralocorticoid receptor is involved in rat and human ocular chorioretinopathy.
    The Journal of clinical investigation, 2012, Volume: 122, Issue:7

    Topics: Adult; Aldosterone; Animals; Central Serous Chorioretinopathy; Choroid; Corticosterone; Eplerenone;

2012
Mineralocorticoid receptor is involved in rat and human ocular chorioretinopathy.
    The Journal of clinical investigation, 2012, Volume: 122, Issue:7

    Topics: Adult; Aldosterone; Animals; Central Serous Chorioretinopathy; Choroid; Corticosterone; Eplerenone;

2012
Mineralocorticoid receptor is involved in rat and human ocular chorioretinopathy.
    The Journal of clinical investigation, 2012, Volume: 122, Issue:7

    Topics: Adult; Aldosterone; Animals; Central Serous Chorioretinopathy; Choroid; Corticosterone; Eplerenone;

2012